HDFC Bank, L&T, Sun Pharma: Citi's Top Picks For 2024
Indian equities are expected to continue their stellar 2023 performance into the current year with the NSE Nifty 50 likely to touch 22,500 by end-December 2024, according to Citi Research.
The research firm forecasts the benchmark Nifty's earnings per share to be 14% by the next financial year. In 2024, it prefers large caps over mid and small caps.
Strong domestic inflows may continue to aid mid and small caps' performance, but the risk-reward ratio is seen better in large caps, Citi said.
In large caps, Citi is 'overweight' on public sector banks, utilities, defence and infrastructure.
Looking Back At 2023
Investors preferred riskier assets like emerging markets' stocks to developed markets' equities, which helped Indian equities post their best performance in 2023, according to Citi.
Indian equities gave returns equal to those of developed markets and outperformed their peer markets.
In the latter part of the year, domestic inflows continued to support Indian benchmark indices' performance.
In sectors, auto, healthcare and industrial outperformed benchmark indices, while financials, utilities and metals underperformed.
Net inflows from foreign institutional investors sharply rebounded last year compared to 2022. India received a net FII inflow of $20 billion in 2023.
Citi's Top Picks For 2024Â
Banks & Diversified Financials
HDFC Bank Ltd.
ICICI Bank Ltd.
IndusInd Bank Ltd.
SBI Life Insurance Co.
Industrial Capital Goods
Larsen & Toubro Ltd.
Bharat Electronics Ltd.
Adani Ports and Special Economic Zone Ltd.
Materials
UltraTech Cement Ltd.
Pharmaceuticals
Sun Pharmaceutical Industries Ltd.
Apollo Hospitals Enterprise Ltd.
TelecomÂ
Bharti Airtel Ltd.
Energy
GAIL (India) Ltd.
Reliance Industries Ltd.
Utilities
NTPC Ltd.
Auto & Transportation
Maruti Suzuki India Ltd.
Eicher Motors Ltd.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.